Atorvastatin as a Pleiotropic Anticancer Agent: Mechanisms and Therapeutic Potential

A 32.1 KB review document summarizes preclinical and clinical evidence for atorvastatin's anticancer properties. Jiaqi Su authored this CC-BY-4.0 licensed review, last updated in April 2026. The text systematically details mechanisms like mevalonate pathway disruption and potential for adjunctive cancer therapy.

Use Cases

• Literature review on statin repurposing based on the summarized preclinical and clinical evidence.
• Analysis of anticancer mechanisms based on the described disruption of the mevalonate pathway and GTPase isoprenylation.
• Study of combination therapy efficacy based on mentions of integrating atorvastatin with immune checkpoint inhibitors.
• Evaluation of molecular pathways based on the review of apoptosis, autophagy, and cell cycle dysregulation.

Strengths

• The document is licensed under CC-BY-4.0, allowing for broad reuse and adaptation.
• It provides a systematic summary of efficacy and molecular mechanisms across various malignancies as stated in the description.

Limitations

• The dataset is a single 32.1 KB DOCX file, indicating a very limited scope and scale.
• Column-level documentation is absent; field semantics must be inferred after download.
• The description is a review summary; the data itself is textual analysis rather than primary experimental data.

Provenance

Source

figshare

Collection Method

Authored literature review.

Freshness

Last updated 2026-04-24 05:40:24; freshness should be verified.